Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.
NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
Mark Mascolini reports on a new study comparing statin indications in male veterans with HIV, HCV or both with three sets of cholesterol guidelines and examining why almost one-third of statin-eligible veterans were not getting the drugs.
The fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) has been evaluated for possible and potential interactions with other drugs.